'Patients pay the tariff': Swiss pharma CEO warns of Trump's generic drug tariff threat

Sandoz CEO Richard Saynor warned that proposed U.S. tariffs of 100% on imported generic drugs from 2028, potentially rising to 200% in 2029, would likely force manufacturers to raise prices or cease supplying some medicines. The risk is material because generics and biosimilars account for about 90% of U.S. prescriptions and much of their drug substance is produced overseas. Separately, Sandoz targeted more than doubling sales by 2035 and lifting core profit margin above 30%, with its sales goal about 13% above current 2035 consensus; shares initially rose 5% before trading 1% lower.

Analysis

A broad generic-drug tariff would not behave like a normal price increase: fragmented manufacturers operating near contribution-margin floors are more likely to rationalize low-volume SKUs than absorb the levy. That creates a second-order shortage risk for hospital systems, wholesalers and PBMs, followed by FDA enforcement discretion, product-specific exemptions, or emergency sourcing—outcomes that would dilute the intended protection for domestic production. The near-term equity read-through is therefore less about tariff pass-through and more about each issuer's API, finished-dose and U.S. manufacturing footprint, which remains unquantified.

For SDZ, the more investable issue is whether its biosimilar pipeline can convert a large loss-of-exclusivity cycle into sustained margin expansion. Biosimilars have materially better barriers to entry than oral generics, but the company’s long-dated growth framework should not be capitalized at face value until launch cadence, tender wins and gross-margin progression validate it. The stated upside versus long-range consensus is a valuation support only if management avoids buying revenue through aggressive pricing or capex.

The market may overstate the direct threat to NVO from early generic semaglutide launches outside the U.S. Patent, regulatory and reimbursement regimes differ materially by geography, while the economically decisive U.S. franchise remains protected by a separate legal timeline. Conversely, a tariff regime that raises low-cost-drug prices could intensify payer pressure on branded manufacturers and strengthen the policy case for biosimilar substitution over the next 6-18 months. A formal tariff notice with product codes, country-of-origin rules and exemption criteria is the key 1-3 month catalyst; absent that, 2028 implementation risk should carry a steep probability discount.

Key Decisions for Investors

• Initiate a 12-18 month long SDZ position only on evidence of biosimilar execution—quarterly biosimilar sales growth, gross-margin expansion and launch milestones—not on tariff headlines. Risk/reward improves if valuation remains below peers despite confirmation of higher-margin mix; exit or reassess on two consecutive quarters of biosimilar underperformance or margin guidance reduction.
• Do not establish a directional generic-tariff trade before the administration publishes covered product codes and exemption rules. Build a monitoring basket of SDZ, TEVA and VTRS, mapping API and finished-dose sourcing plus U.S. capacity; the company with the highest imported low-margin SKU exposure is a potential short only after rules make its inability to pass through costs measurable.
• Avoid using NVO as a near-term short expression of generic semaglutide competition. Treat non-U.S. generic launches as a sentiment risk rather than an earnings impairment until U.S. legal protection, payer access or realized GLP-1 net pricing changes; a material U.S. price/guidance revision would falsify this restraint.
• Consider a long SDZ / short VTRS relative-value screen over 6-12 months, but execute only if sourcing analysis shows SDZ has no worse tariff exposure and its biosimilar revenue mix continues to outgrow. Target a 10-15% relative move; stop if VTRS demonstrates superior margin resilience or SDZ’s biosimilar launch timing slips.